The WHO Foundation has announced an expanded collaboration with Novo Nordisk to support global efforts to support health systems in the fight against the rising burden of heart, kidney and metabolic diseases, including obesity and diabetes.
Novo Nordisk has committed a total of $7.9 million to support these efforts, with an initial commitment of $2.9 million in 2024 and then another $5 million in December 2025.
The contribution will enable the WHO Foundation to support WHO's broader efforts to combat non-communicable diseases (NCDs) through prevention, early action and increased primary health care, especially in low- and middle-income countries where health systems often reach their limits.
"Heart, kidney and metabolic diseases are complex diseases that primarily require prevention concepts that are embedded in strong and resilient health systems," said Anil Soni, CEO of the WHO Foundation. "By supporting WHO's leadership in prevention, we can strengthen the scientific and health foundations that countries need to respond effectively and equitably."
